Financial Data and Key Metrics Changes - Full-year revenue for 2025 was $3.245 billion, a decrease of 0.5% compared to the prior year, while Q4 revenue was $846.3 million, down 1.2% year-over-year but up 1.7% on an organic basis [16][17] - Adjusted EBITDA for the full year was $616.7 million with an Adjusted EBITDA Margin of 19.0%, while Q4 Adjusted EBITDA was $163.1 million with a margin of 19.3% [19][20] - Free Cash Flow for the full year was $219.4 million, exceeding the top end of guidance [21] Business Line Data and Key Metrics Changes - Sleep Health net revenue was $372.3 million, up 4.4% year-over-year, with new starts approximately 130,600, reflecting a 6% increase [17] - Respiratory Health net revenue was $178.2 million, up 7.8% year-over-year, with oxygen and vent new starts increasing by about 4% and 5% respectively [18] - Diabetes Health net revenue was $158.5 million, down 7.4% year-over-year, with patient retention at an all-time record but new starts remaining soft [18] - Wellness at Home net revenue declined by 16.1% primarily due to the disposition of non-core assets [19] Market Data and Key Metrics Changes - Patient census records were set in Sleep Health, Respiratory Health, and Wellness at Home, with significant growth in patient numbers across these segments [4][5] - The company achieved a flat year-over-year patient census in Diabetes Health, with improved retention offsetting slower new starts [6] Company Strategy and Development Direction - The company implemented a new operating model in 2025 aimed at standardization and process maturity, which is expected to drive accelerated growth and improved financial performance in 2026 [3] - The focus remains on debt reduction and strengthening the balance sheet, with $250 million in debt reduced during the year [7][22] - The company is actively pursuing acquisitions to expand its footprint and increase patient access, while also targeting home medical equipment providers [14][15] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the operational foundation and strategic focus, stating that the company is in the best condition it has ever been as it enters 2026 [15] - The company anticipates revenue growth of 6%-8% for 2026, driven by new capitated agreements and organic growth [24] - Management highlighted the importance of aligning incentives in the healthcare market and the ongoing interest in capitated arrangements [44] Other Important Information - The company received favorable outcomes from CMS regarding competitive bidding, providing stability for core products [14] - A legal settlement of $14.5 million was finalized, addressing a civil debt collection class action, which management believes will de-risk the business moving forward [29][30] Q&A Session Summary Question: Clarification on the legal settlement - Management confirmed the settlement relates to a civil debt collection class action and is final, addressing all claims in that state [29][30] Question: Impact of investment on guidance and margin cadence - Management provided insights on expected revenue growth and Adjusted EBITDA margin improvements throughout 2026, with specific quarterly expectations [36][38] Question: Pipeline of capitated agreements - Management discussed ongoing conversations and market interest in capitated arrangements, emphasizing the time required to finalize such contracts [44][46] Question: Update on diabetes segment growth - Management noted improvements in retention and plans to grow the diabetes sales force to enhance new starts in 2026 [48][49] Question: Infrastructure readiness for new healthcare partnerships - Management confirmed readiness for upcoming start dates and highlighted investments made to support new capitated arrangements [52][53]

Core Insights - Medtronic and Mindray are expanding their strategic partnership in patient monitoring technology from traditional hospital settings to Ambulatory Surgery Centers (ASCs) in the U.S. This aims to simplify access and integration of advanced monitoring technologies, enhance clinical efficiency, and improve patient care quality while reducing operational costs [2][10] - The collaboration reflects a shift in the healthcare monitoring technology landscape, adapting to the changing service delivery models in the medical field [2][10] Technical Foundation: Core Technologies and Applications in Perioperative Monitoring - Patient monitoring devices are essential infrastructure in modern healthcare, used for real-time tracking of physiological parameters such as blood oxygen saturation, carbon dioxide levels, and brain activity, particularly in surgery, critical care, and anesthesia management [5][6] - These technologies are crucial for assessing patient condition changes and supporting clinical decision-making [6] Strategic Extension: Adapting to ASC Scenarios - Previously, Medtronic and Mindray collaborated primarily in hospital settings focused on critical care and perioperative environments. The new partnership extends to ASCs, indicating a shift from high-intensity, complex scenarios to low-invasiveness, operational efficiency, and cost-sensitive outpatient settings [7][10] - ASCs emphasize ease of use, procurement convenience, and efficient support rather than solely complex monitoring capabilities, prompting suppliers to rethink market positioning and product offerings [7][10] Industry Impact and Collaborative Value - This partnership not only involves product integration but may also reshape equipment selection, clinical operations, and service support standards in the ASC sector [12] - For medical device manufacturers, this collaboration signifies that large technology suppliers are entering more niche markets through joint solutions. For ASC providers, integrated monitoring product offerings can lower procurement and training costs while enhancing clinical efficiency [12]